natgillin/translations-raw huggingface dataset:
Device (1;10) according to any one of the preceding claims wherein the thickened portion (5) is placed on the lower surface of the enlarged portion (2). 
Sredstvo (1; 10) prema bilo kojem od prethodnih zahtjeva, pri čemu se deblji dio (5) nalazi na donjoj površini većeg dijela (2).
Device (1;10) according to claim 4 wherein the two elongated stem portions (3,4) have different lengths. 
Sredstvo (1; 10) prema zahtjevu 4, pri čemu dva izdužena noseća dijela (3,4) imaju različite dužine.
Device (1;10) according to any one of the preceding claims 1-3 wherein the thickened portion (5) is placed on the upper surface of the enlarged portion (2). 
Sredstvo (1; 10) prema bilo kojem od prethodnih zahtjeva 1-3, pri čemu se deblji dio (5) nalazi na gornjoj površini većeg dijela (2).
Device (1;10) according to claim 6 wherein the two elongated stem portions (3,4) have substantially equal lengths. 
Sredstvo (1; 10) prema zahtjevu 6, pri čemu dva izdužena noseća dijela (3,4) imaju u biti iste dužine.
Device (1;10) according to any one of the preceding claims wherein two reinforcing metal plates (8) are provided, each of them having a sleeve (9) to be fitted around a respective elongated stem portion (3,4). 
Sredstvo (1; 10) prema bilo kojem od prethodnih zahtjeva, pri čemu su predviđene dvije metalne pločice (8) za ojačanje, a svaka od njih ima rukavac (9) koji treba postaviti oko odgovarajućeg izduženog nosećeg dijela (3,4).
A human or humanized antibody or fragment thereof containing an antigen-binding region which specifically binds to an epitope of CD38, wherein the epitope comprises one or more amino acid residues comprised in one or more of the amino acid stretches taken from the list of amino acid stretches 44-66, 82-94, 142-154, 148-164, 158-170, or 192-206 of CD38 (SEQ ID NO: 22). 
Humano ili humanizirano antitijelo ili njegov fragment koje/koji sadrži antigen-vežuću regiju koji se specifično veže za epitop CD38, pri čemu epitopa sadrži jednu ili više aminokiselinskih ostataka sadržanih u jednom ili više aminokiselinskih nizova uzetih sa popisa aminokiselinskih nizova 44-66, 82-94, 142-154, 148-164, 158-170, ili 192-206 CD38 (SEQ ID NO: 22).
The cell according to claim 13, wherein said cell is a bacterial cell or a mammalian cell. 
Stanica prema patentnom zahtjevu 13, pri čemu je navedena stanica bakterijska stanica ili stanica sisavca.
A synthetic oligonucleotide-based compound comprising two oligonucleotides that are complementary to a single-stranded RNA sequence, wherein the oligonucleotides are linked at their 5'-ends, such that the oligonucleotide-based compound has two accessible 3'-ends and the oligonucleotide-based compound specifically hybridizes to and inhibits the expression of the single-stranded RNA sequence. 
Sintetski spoj na bazi oligonukleotida koji sadrži dva oligonukleotida koji su komplementarni jednolančanoj RNA sekvenci, naznačen time da su oligonukleotidi povezani na svojim 5'-krajevima, tako da spoj na bazi oligonukleotida ima dva dostupna 3'-kraja i da spoj na bazi oligonukleotida specifično hibridizira na i inhibira ekspresiju jednolančane RNA sekvence.
The oligonucleotide-based compound according to claim 9, wherein the oligonucleotides are complementary to an RNA encoding Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin, VEGF, or a TLR. 
Spoj na bazi oligonukleotida prema zahtjevu 9, naznačen time da je oligonukleotid komplementaran RNA koja kodira Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin, VEGF, ili TLR.
The oligonucleotide-based compound according to any one of claims 1 to 7 for use in a method for therapeutically treating a mammal having a disease or disorder mediated by a protein, wherein the oligonucleotides are complementary to the single-stranded RNA encoding the protein. 
Spoj na bazi oligonukleotida prema bilo kojem od zahtjeva 1 do 7 za upotrebu u postupku za terapijski tretman sisavca koji ima bolest ili poremećaj posredovan proteinom, naznačen time da su oligonukleotidi komplementarni jednolančanoj RNA koja kodira protein.
The oligonucleotide-based compound according to any one of claims I to 7 for use in a method for preventing a disease or disorder mediated by a protein in a mammal at risk for developing the disease or disorder, wherein the oligonucleotides are complementary to the single-stranded RNA encoding the protein. 
Spoj na bazi oligonukleotida prema bilo kojem od zahtjeva 1 do 7 za upotrebu u postupku prevencije bolesti ili poremećaja posredovanog proteinom kod sisavca koji ima rizik za razvoj bolesti iki poremećaja, naznačen time da su oligonukleotidi komplementarni jednolančanoj RNA koja kodira protein.
The oligonucleotide-based compound according to claim 12 or 13 wherein the disease or disorder is selected from cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma, bacterial, viral or fungal infection, or a disease caused by a pathogen. 
Spoj na bazi oligonukleotida prema zahtjevu 13 ili 14, naznačen time da je bolest ili poremećaj izabran između raka, autoimunog poremećaja, upale dišnih putova, upalnih poremećaja, infektivnih bolesti, kožnih poremećaja, alergija, astme, bakterijske, virusne ili gljivične infekcije, ili bolesti uzrokovane patogenom.
The oligonucleotide-based compound according to any one of claims 9 to 15, which is to be administered in conjunction with one or more vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, TLR agonist, TLR antagonist, siRNA molecules, miRNA molecules, antisense oligonucleotides, aptamers, proteins, peptides, gene therapy vectors, DNA vaccines, adjuvants, antagonists of protein activity, kinase inhibitors, chemotherapeutic agents, targeted therapeutic agents, co-stimulatory molecules or combination thereof. 
Spoj na bazi oligonukleotida prema bilo kojem od zahtjev 9 do 15, koji se primjenjuje u kombinaciji s jednim ili više cjepiva, antigena, protutijela, citotoksičnih sredstava, alergena, antibiotika, TLR agonista, TLR antagonista, siRNA molekula, rniRNA molekula, antisense nukleotida, aptamera, proteina, peptida, vektora genske terapije, DNA cjepiva, adjuvansa, antagonista proteinske aktivnosti, kinaznih inhibitora, kemoterapeutika, ciljanih terapijskih sredstava, ko-stimulatornih molekula ili njihovih kombinacija.
The composition according to claim 8 further comprising one or more vaccines, antigens, antibodies, cytotoxic agents, chemotherapeutic agents, kinase inhibitors, allergens, antibiotics, agonists, antagonists, antisense oligonucleotides, ribozymes, RNAi molecules, siRNA molecules, miRNA molecules, aptamers, proteins, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof. 
Kompozicija prema zahtjevu 8 koja nadalje sadrži jedno ili više cjepiva, antigena, protutijela, citotoksičnih sredstava, kemoterapeutskih sredstava, inhibitora kinaze, alergena, antibiotika, agonista, antagonista, antisense oligonukleotida, ribozima, RNA molekula, siRNA molekula, miRNA molekula, aptamera, proteina, vektora genske terapije, DNA cjepiva, adjuvansa, ko-stimulatornih molekula ili njihove kombinacije.
A solid oral dosage form comprising: 
Čvrsti oralni dozirni oblik u obliku tablete koji sadrži:
An oligonucleotide-based compound comprising two single-stranded oligonucleotides that are independently 15 to 40 nucleotides in length and are complementary to the same single-stranded RNA sequence, wherein the oligonucleotides are linked at their 5'-ends, optionally through a linker, such that the compound has two accessible 3'-ends. 
Sintetski spoj na bazi oligonukleotida koji sadrži dva oligonukleotida koji su komplementarni jednolančanoj RNA sekvenci, naznačen time da su oligonukleotidi povezani na svojim 5'-krajevima, tako da spoj na bazi oligonukleotida ima dva dostupna 3'-kraja i da spoj na bazi oligonukleotida specifično hibridizira na i inhibira ekspresiju jednolančane RNA sekvence.
A composition comprising degarelix for use in the treatment of skeletal metastasis or bone metastasis. 
Pripravak koji sadrži degareliks za uporabu pri liječenju skeletnih metastaza ili metastaza kostiju, naznačen time da su skeletne metastaze ili metastaze kostiju posljedica karcinoma prostate.
A composition for use accoring to claim 1 wherein the treatment reduces the level of skeletal metastasis or bone metastasis, or maintains the same level of skeletal metastasis or bone metastasis without increase. 
Pripravak za uporabu prema zahtjevu 1 naznačen time da liječenje smanjuje razinu skeletnih metastaza ili metastaza kostiju, ili za održavanje iste razine skeletnih metastaza ili metastaza kostiju bez povećanja.
A composition comprising degarelix for use in reducing the level of skeletal metastasis or bone metastasis, or maintaining the same level of skeletal metastasis or bone metastasis without increase. A composition for use according to any preceding claim wherein the skeletal metastasis or bone metastasis results from prostate cancer. 
Pripravak koji sadrži degareliks za uporabu za smanjenje razine skeletnih metastaza ili metastaza kostiju, ili za održavanje iste razine skeletnih metastaza ili metastaza kostiju bez povećanja, naznačen time da su skeletne metastaze ili metastaze kostiju posljedica karcinoma prostate.
A composition for use according to any preceding claim wherein the subject to be treated is identified by a step of testing the serum alkaline phosphatase (S-ALP) level of a potential subject and then selecting the subject for treatment If the subject's baseline S-ALP level Is 150 IU/L or greater, e.g. 
Pripravak za uporabu prema bilo kojem zahtjevu od 1 do 8 naznačen time da je subjekt koji se treba liječiti identificiran s korakom testiranja razine alkalne fosfataze u serumu (S-ALP) kod potencijalnog subjekta i zatim slijedi odabir subjekta za liječenje ako je osnovna razina S-ALP 150 IU/L ili veća, npr.
A composition for use according to any preceding claim wherein the subject to be treated is identified by a step of testing the prostate-specific antigen (PSA) level of a potential subject and then selecting the subject for treatment if the subject's PSA level is greater than or equal to 50 ng/mL. 
Pripravak za uporabu prema bilo kojem zahtjevu od 1 do 8 naznačen time da je subjekt koji se treba liječiti identificiran s korakom testiranja razine prostata specifičnog antigena (PSA) kod potencijalnog subjekta i zatim slijedi odabir subjekta za liječenje ako je razina PSA kod subjekta veća od ili jednaka 50 ng/mL.
A tie comprising: a head (10); 
Vezica koja se sastoji od: glave (10);
System as claimed in claim 1, characterized in that the lighting means (20) are able and adapted to emit a lighting spectrum which can be adapted to an intended photosynthesis and/or mode of growth of the plant to be cultivated. 
Sustav sukladno Zahtjevu 1, naznačen time da su rasvjetna sredstva (20) sposobna i prilagođena za emitiranje svjetlosnog spektra koji može biti prilagođen namjeravanoj fotosintezi i/ili načinu rasta biljke koja se uzgaja.
System as claimed in claim 2, characterized in that the lighting means comprise a set of light-emitting diodes, these diodes being able and adapted to emit radiation at different wavelengths and being individually controllable, optionally in groups. 
Sustav sukladno Zahtjevu 2, naznačen time da rasvjetna sredstva sadrže set dioda koje emitiraju svjetlo (21), ove su diode sposobne i prilagođene emitiranju zračenja različitih valnih duljina i koje se mogu individualno kontrolirati, po izboru u skupinama.
System as claimed in one or more of the foregoing claims, characterized in that the leaf heating means (30) comprise at least one heat source able and adapted to irradiate the leaf with infrared radiation. 
Sustav sukladno jednom ili više prethodnih Zahtjeva, naznačen time da sredstva za zagrijavanje lišća (30) sadrže barem jedan izvor topline sposoban i prilagođen za zračenje lišća infracrvenim zrakama.
System as claimed in claim 4, characterized in that the lighting means and the heat source are accommodated in mutually separated fittings. 
Sustav sukladno Zahtjevu 4, naznačen time da su rasvjetna sredstva i izvor topline smješteni u međusobno odvojenim dijelovima.
System as claimed in one or more of the foregoing claims, characterized in that a control is provided between the leaf heating means and root temperature control means which imposes a mutual dependence on the leaf temperature and the root temperature. 
Sustav sukladno jednom ili više prethodnih Zahtjeva, naznačen time da je omogućena kontrola između sredstava za zagrijavanje lišća i temperature korijena koja pretpostavlja međusobnu ovisnost temperature lišća i temperature korijena.
Method for growing a plant in at least partly conditioned manner, wherein actinic light is supplied to the plant, wherein a root temperature of a root system of the plant is maintained at a desired value, and wherein a carbon dioxide assimilation management of a leaf system of the plant is influenced, and a supply of actinic light, the root temperature and the carbon dioxide assimilation management are adapted to each other, characterized in that the carbon dioxide assimilation management is influenced by regulating a leaf temperature of the leaf system so that it differs from an ambient temperature. 
Postupak uzgoja biljke na barem djelomično uvjetovan način, pri čemu je aktinično svjetlo primjenjeno na biljku, pri čemu je temperatura korijenskog sustava biljke održavana u željenoj vrijednosti, te pri čemu se utječe na asimilaciju ugljičnog dioksida u sustav lišća biljke, a primjena aktiničnog svjetla, temperature korijena i unos ugljičnog dioksida biljke podložna je promjenama, te su primjena aktiničnog svjetla, temperature korijena i unos ugljičnog dioksida biljke međusobno prilagođeni, naznačen time da je upravljanje unosom ugljičnog dioksida pod utjecajem regulacije temperature lišća tako da se razlikuje od temperature okoliša.
Method as claimed in claim 8, characterized in that the supply of light, the root temperature and the leaf temperature are adapted to each other depending on the plant. 
Postupak sukladno Zahtjevu 8, naznačen time da su opskrba svjetlom, temperatura korijena i temperatura lišća međusobno prilagođeni ovisno o biljci.
Method as claimed in claim 8 or 9, characterized in that actinic artificial light is supplied with a spectrum adapted to an intended photosynthesis and/or mode of growth of the plant. 
Postupak sukladno Zahtjevima 8 ili 9, naznačen time da se aktinično svjetlo primjenjuje u spektru prilagođenom namjeravanoj fotosintezi i/ili načinu rasta biljke.
Method as claimed in claim 10, characterized in that the artificial light spectrum, a leaf temperature of the leaf and the root temperature are controlled individually of each other but in mutual relation, depending on the plant. 
Postupak sukladno Zahtjevu 10, naznačen time da su spektar umjetnog svjetla, temperatura lišća i temperatura korijena individualno kontrolirani, ali u međusobnom odnosu, ovisno o biljci.
A method according to claim 1, characterised in that the system further comprises at least one feed point (18) which is arranged by a waste chute (17) into connection with the waste container (10) or the transport container. 
Postupak prema zahtjevu 1, naznačen time da sustav dodatno sadrži barem jednu napojnu točku (18) koja je postavljena pored silaznog žlijeba za otpad (17) i spojena je sa spremnikom za otpad (10) ili transportnim spremnikom.
A method according to claim 1 or 2, characterised in that there are arranged several of feed points (1, 8, 18) distributedly in the area of the system. 
Postupak prema zahtjevu 1 ili 2, naznačen time da postoji postavljeno nekoliko napojnih točaka (1, 8, 18) koje su raspoređene u području sustava.
A method according to any one of claims 1-4, characterised in that, in the system, the waste container (10) is conveyed to a transport carriage (10') or a transport truck by a conveying device or a lifting device or manually. 
Postupak prema bilo kojem zahtjevu od 1-4, naznačen time, da se u sustavu, spremnik za otpad (10) prenosi do kolica za transport (10') ili do transportnog kamiona pomoću transportnog uređaja ili uređaja za podizanje ili ručno.
The container assembly (100) according to claim 9, further comprising: 
Sklop posude (100) prema zahtjevu 9, koji dalje sadrži:
Multi layered covering material according to any previous claim wherein material for said outer layer (1) is selected from at least one of the following materials: leather, preferably fine grain leather, cotton, hemp, linen. 
Višeslojni pokrivni materijal prema bilo kojem prethodnom zahtjevu, naznačen time da se materijal za spomenuti vanjski sloj (1) bira od najmanje jednog od sljedećih materijala: koža, poželjno koža fine granulacije, pamuk, kudjelja, lan.
A pharmaceutical composition for use in the treatment of skin wounds comprising the olive leaf extract according to claim 1 adapted for topical administration. 
Farmaceutski pripravak za upotrebu u tretiranju kožnih rana koji sadrži ekstrakt lista masline prema zahtjevu 1., prilagođen za topičku administraciju.
A pharmaceutical composition for use according to claim 2 in the form of a cream, ointment, balsam, solution, emulsion, transdermal patch or salve. 
Farmaceutski pripravak za upotrebu prema zahtjevu 2., u obliku kreme, masti, balzama, otopine, emulzije, transdermalnog flastera ili melema.
A pharmaceutical composition for use according to any of claims 2 to 6, wherein the treatment comprises application of the pharmaceutical composition to the wound for the first time up to 14 days after the onset of the damage. 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 2. do 6., naznačen time da se tretiranje sastoji u apliciranju farmaceutskog pripravka na ranu prvi put do 14 dana nakon početka oštećenja.
an opposing interior surface (201); 
suprotnu unutrašnju površinu (201);
a generally circular outer peripheral edge (214); 
običan kružni vanjski periferni rub (214);
A container assembly (100) characterized by the child-resistant cap (200) according to claim 1 in combination with a container (110), wherein: 
Sklop posude (100) okarakteriziran poklopcem siguran za djecu (200) prema zahtjevu 1 u kombinaciji sa posudom (110), gdje:
the container (110) comprises: 
posuda (110) sadrži:
a bottom (124) having an outer periphery; 
dno (124) koje ima vanjsku periferiju;
A compound of formula (I): wherein 
Tvar formule (I):
provided that no more than three of X1-X5 represent nitrogen; 
uz uvjet da ne više od tri X1-X5 predstavljaju dušik;
represents a single or double bond, such that at least one bond within the 5 membered ring system is a double bond; 
[image] predstavlja jednostruku ili dvostruku vezu, tako da je barem jedna veza unutar 5-eročlanog prstenastog sustava dvostruka veza;
represents an aryl or heterocyclyl group optionally substituted by one or more Rb groups; 
predstavlja aril ili heterociklil grupu opcionalno supstituiranu jednom ili više Rb grupa;
A compound as defined in claim 1 or claim 2 wherein A represents a phenyl or pyridyl group optionally substituted by one or more Ra groups. 
Tvar definirana u patentnom zahtjevu 1 ili patentnom zahtjevu 2 pri čemu A predstavlja fenil ili piridil grupu opcionalno supstituiranu jednom ili više Ra grupama.
A compound as defined in any one of claims 1, 2, 4, 5 or 6 wherein R2 represents oxazole, oxadiazole, triazole, tetrazole, thiadiazole or oxathiadiazole optionally substituted by one or more methyl, ethyl or-S-methyl groups. 
Tvar definirana u bilo kojem od patentnih zahtjeva 1, 2, 4,5 ili 6 pri čemu R2 predstavlja oksazol, oksadiazol, triazol, tetrazol, tiadiazol ili oksatiadiazol opcionalno supstituiran jednom ili više metil, etil ili –S-metil grupama.
A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 14. 
Farmaceutski sastav obuhvaća tvar formule (I) definiranu u bilo kojem od patentnih zahtjeva 1 do 14.
An orally administrable pharmaceutical pellet which comprises a core and an enteric coating, wherein the core comprises a pharmaceutically effective amount of the epidermal growth factor and sulphur-containing antioxidant selected from the group consisting of methionine and K2S2O7. 
Oralno primjenjive farmaceutske pelete koje imaju jezgru i gastrorezistentnu ovojnicu, gdje jezgra sadrži farmaceutski učinkovitu količinu epidermalnog faktora rasta i antioksidans koji u svom sastavu ima sumpor, izabran iz skupine koja obuhvaća metionin i K2S2O7.
The pellet according to claim 3, where the alkaline agent is disodium phosphate. 
Pelete prema zahtjevu 3, gdje je alkalno sredstvo dinatrijev fosfat.
The pellet according to claim 3, where the glidant is talc. 
Pelete prema zahtjevu 3, gdje je sredstvo za podmazivanje talk.
The pellet according to claim 3, where the surfactant is sodium lauryl sulphate. 
Pelete prema zahtjevu 3, gdje je surfaktant natrijev lauril sulfat.
% by weight of disodium phosphate; and 
% težine dinatrijevog fosfata; i
The pellet according to any of the claims 1-11, further comprising an intermediate coating layer which comprises at least a modified release polymer. 
Pelete prema bilo kojem od zahtjeva 1-11, dalje sadrže međusloj ovojnice koji obuhvaća barem polimer s prilagođenim oslobađanjem.
The pellet according to claim 12, where the intermediate coating layer further comprising a glidant. 
Pelete prema zahtjevu 12, gdje međusloj ovojnice dalje obuhvaća sredstvo za podmazivanje.
The pellet according to any of the claims 12-13, where the modified release polymer is selected from the group consisting of polyacrylates, polymethacrylates, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and mixtures thereof. 
Pelete prema bilo kojem od zahtjeva 12-13, gdje se polimer s prilagođenim oslobađanjem izabire iz skupine koja obuhvaća poliakrilate, polimetakrilate, etilcelulozu, hidroksipropilcelulozu, hidroksipropilmetilcelulozu i njihove mješavine.
The pellet according to any of the claims 12-14, where the modified release polymer is a polymer of poly(ethyl acrylate/methylmethacrylate) esters. 
Pelete prema bilo kojem od zahtjeva 12-14, gdje je polimer s prilagođenim oslobađanjem polimer od estera poli(etilakrilata/metilmetakrilata).
coating of the inert nucleus by spraying an aqueous suspension which comprises the epidermal growth factor, the antioxidant and the pharmaceutically acceptable excipients; 
oblaganje inertne jezgre putem sprejanja vodene suspenzije koja sadrži epidermalni faktor rasta, antioksidans i farmaceutski prikladne pomoćne tvari;
coating the nucleus of step (b) by spraying a suspension which comprises the enteric coating polymer and the pharmaceutically acceptable excipient; and 
oblaganje jezgre iz koraka (b) sprejanjem suspenzije koja sadrži gastrorezistentni polimer za ovojnicu i farmaceutski prikladnu pomoćnu tvar; i
where the temperature of each step of the process is up to 40°C. 
gdje je temperatura svakog koraka postupka do 40°C.
iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; 
iii) eluiranje navedenog 223Ra s navedene jako bazične anionske izmjenjivačke smole koristeći prvu mineralnu kiselinu u alkoholnoj vodenoj otopini zbog nastanka prve otopine eluiranog 223Ra;
iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and 
iv) unos 223Ra iz prve otopine eluiranog 223Ra na jako kiselu kationsku izmjenjivačku smolu; i
eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. 
eluiranje 223Ra s nevedene jako kisele kationske izmjenjivačke smole koristeći drugu mineralnu kiselinu u vodenoj otopini u svrhu dobivanja druge eluirane otopine.
eluting said 227Ac and 227Th from said strong base anion exchange resin using a third mineral acid in aqueous solution, whereby to provide a mixture of 227Ac and 227Th, wherein step occurs at any time following step ii). 
eluiranja navedenog 227Ac i 227Th s navedene jako bazične anionske izmjenjivačke smole koristeći treću mineralnu kiselinu u vodenoj otopini, zbog stvaranja smjese 227Ac i 227Th, gdje se ovaj korak pojavljuje bilo kada nakon koraka ii).